Status:
COMPLETED
Efficacy and Safety of Fire Needle Therapy Combined With Cortex Phellodendri Compound Fluid Wet Compress for Acute Herpes Zoster: a Randomized Controlled Trial.
Lead Sponsor:
Second Affiliated Hospital of Xi'an Jiaotong University
Conditions:
Acute Herpes Zoster
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Herpes zoster (HZ) results from a reactivation of varicella-zoster virus (VZV), which causes primary infection leading to chickenpox and remains latent in the ganglia. Fire needle therapy is a non-pha...
Detailed Description
Herpes zoster (HZ) results from a reactivation of varicella-zoster virus (VZV), which causes primary infection leading to chickenpox and remains latent in the ganglia. Fire needle therapy is a non-pha...
Eligibility Criteria
Inclusion
- males and females, aged 18-80 years old;
- diagnosed as acute HZ with the course of disease within 7 days;
- without history of other treatment before enrollment.
Exclusion
- specific types of HZ, including Ramsay Hunt Syndrom, ophthalmic, disseminated, deep, purpuric and central nervous system HZ;
- pregnancy and lactation;
- allergic to the related Chinese herbals;
- patients with contraindications to penciclovir, mecobalamin and pregabalin; (e) history of hypertrophic scar or keloid;
- (f) severe cardiovascular, cerebrovascular, digestive, urinary or hematopoietic disease; (g) mental disease; (h) coagulation disorders.
Key Trial Info
Start Date :
January 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2024
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT06985589
Start Date
January 1 2024
End Date
August 31 2024
Last Update
May 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China, 710000